17-01-2013

NovAliX SAS announced that it has entered into a fragment-based drug discovery alliance with Kyowa Hakko Kirin Co., Ltd., Japan. Within the alliance, the companies will collaborate to develop novel drug candidates against protein-protein interaction targets. Under the terms of the agreement ...

more

23-10-2012

NovAliX has announced that it has appointed pharma research executive Dr Luc Van Hijfte as CSO Drug Discovery.Dr. Van Hijfte brings a wealth of experience in pharmaceutical research with over 25 years spent in drug discovery. He joined from Janssen, a J&J company, where he served as Head of ...

more

16-01-2012

NovAliX SAS announced that it has entered into a multi-target integrated drug discovery collaboration with Teijin Pharma Limited of Tokyo, Japan.Within the alliance the companies will collaborate to develop novel drug candidates against multiple targets across different therapeutic areas. ...

more

14-09-2011

NovAliX announced that it has entered into a multi-year drug research collaboration in the field of trisomy 21 with the Fondation Jérôme Lejeune.NovAliX will use its expertise and capabilities in medicinal chemistry and structural biology to develop small molecule lead candidates targeting ...

more

31-08-2011

NovAliX announces that it has entered into drug discovery collaboration in the field of osteoarthritis with Galapagos.Under the terms of this agreement NovAliX will be responsible for the discovery of specific small molecule lead candidates for a novel, validated osteoarthritis target chosen ...

more

18-11-2010

NovAliX SAS announced that it has entered into a definitive agreement to acquire a majority interest in Graffinity Pharmaceuticals GmbH. Financial details of the transaction were not disclosed. NovAliX’ President, Stephan Jenn stated: "The acquisition of Graffinity will be a significant ...

more